Medicine supply
A marketing authorisation works to ensure that when a medicine reaches a patient it works in the same high quality way every time.
Medicines are highly regulated and the听Medicines and Healthcare Products Regulatory Agency (MHRA) issues听a 鈥榤arketing听authorisation鈥� for every medicine.
The marketing authorisation governs听not only what the medicine is for and how it should be used, but also the details of the formulation, storage requirements and shelf life, so that the medicine that reaches patients听works and听is听of听the same听high quality听every time.
To learn more about the work of the MHRA, visit the鈥齭ection of the MHRA website.听
The MHRA also issues听鈥榤anufacturing authorisations鈥櫶齱hich entitle a company to manufacture medicines in the UK.鈥鼵ompanies听need to听demonstrate that they comply with good manufacturing practice and pass regular inspections of the manufacturing site. To find out more about this, visit the听听听
The 大发六合彩 works through its鈥疨harmaceutical Quality Expert Network鈥痶o monitor regulatory activity on these topics and participate in the development of legislation at both national and European levels.鈥疶he Network also facilitates the exchange between members of good practice in these important areas.听
Environmental health and safety听
Good environmental health and safety performance is a major consideration in all aspects of pharmaceutical industry activity.听
Through the鈥疎nvironmental Health听and Safety Network, we monitor regulatory activity on these topics and participate actively in the development of legislation at both national and European levels, as well as facilitating the sharing of鈥痝ood practice amongst member companies.鈥�
Every day millions of patients rely on medicines supplied by the pharmaceutical industry.
The manufacture and selling of counterfeit medicines is an issue of increasing concern throughout the world. There are potentially fatal consequences for those who inadvertently take such products.
The Falsified Medicines Directive is legislation passed by the European Union Parliament, which aims to increase the security of the manufacturing and delivery of medicines across Europe and protect patients and prevent falsified medicines from entering the supply chain.
Related content in this section:
Last modified: 14 July 2022
Last reviewed: 25 July 2022
Last modified: 23 May 2024
Last reviewed: 23 May 2024